Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, raised $176 million by offering 9.8 million ADSs at $18, within the range of $17 to $19.
The company's pipeline contains cNeT candidate ATL001, which is currently being evaluated in two open-label Phase 1/2a trials for advanced NSCLC and metastatic or recurrent melanoma, with interim data expected in the 2H22. The company expects to file INDs for its earlier stage programs, HNSCC and RCC, in the 2H21 and the 2H23, respectively.
Achilles Therapeutics plans to list on the Nasdaq under the symbol ACHL. J.P. Morgan, BofA Securities and Piper Sandler acted as lead managers on the deal.
